- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Asia-Pac's Anti-hypertensive Therapeutics Market to Hit Nearly $20 Billion by 2021
July 14, 2015.
The anti-hypertensive therapeutics market in the Asia-Pacific countries of Australia, India, China, and Japan will grow in value from $15.7 billion in 2014 to $19.9 billion by 2021, according to GBI Research.
The company’s report states that this modest market growth rate will be primarily due to the lack of hypertension awareness, which leads to low diagnosis and treatment rates.
GBI analyst Aswini Nath said Japan is the largest anti-hypertensive therapy market among the four APAC countries, valued at $8.1 billion in 2014 and representing 52% of the region’s anti-hypertensive treatment space.
The report also states that India’s anti-hypertensive therapeutics market value will expand at the fastest CAGR of 12.6%, more than doubling from $0.8 billion in 2014 to $1.9 billion by 2021.
For more, see the report: Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2021 -Increasing Prevalence of Hypertension Drives Market Growth despite Weak Pipeline
